Key Takeaways (Executive Summary) Part 1: The Compounding Regulatory Architecture The Market Context The U.S. compounding pharmacy sector is not […]

Key Takeaways (Executive Summary) Part I: The R&D Productivity Crisis and the AI Imperative The Economics Are Broken The math

How to convert raw patent filings into predictive R&D roadmaps that de-risk pipelines, price M&A targets, and identify white space

The complete operational guide for pharma IP teams, portfolio managers, and supply chain leads on converting patent intelligence into production

Part I: The $15 Billion Paradox — A Market That Grows With the Brake On The pharmaceutical excipients market is

Every day a blockbuster drug holds patent protection is worth, on average, $8.2 million in revenue. That figure makes the

Executive Summary Between 2023 and 2028, an estimated $356 billion in worldwide branded pharmaceutical sales sit exposed to patent expiration.

Executive Intelligence Brief Biosimilar development is not generic drug development with more paperwork. It is a $100M-to-$300M scientific undertaking that

Executive Summary Every month, the FDA issues a batch of Tentative Approvals (TAs) for generic drug applications. Most market participants